ClinicalTrials.gg
RecruitingNCT06580314Updated Nov 9, 2026

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

A Phase 3 interventional study of Bevacizumab and Biospecimen Collection in Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma and Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, sponsored by NRG Oncology. Recruiting at 709 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionOvarian NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ovarian Neoplasms
Why
  1. The study's listed conditions name Ovarian Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NRG Oncology · Phase 3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 9, 2026Site recruiting status changed15 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Planned enrollment
7th of 106
880 · median 52
Started
2025
with 8 others
Phase 3
18 of 106
4 open now
Primary completion
2034-12
later than 31 of 31 live
Registered
91st of 106
by date

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 7th largest by planned enrollment, is one of 9 that started in 2025, is one of 18 in phase 3, reaches primary completion later than 31 of the 31 other live ones, and was the 91st registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine investigator assessed progression-free survival using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (non-inferiority) for one versus (vs.) two years of maintenance olaparib.

SECONDARY OBJECTIVES:

I. To evaluate overall survival (OS360) in the modified intent to treat (ITT) population, with time at risk for progression/death starting 360 days after randomization.

II. To evaluate progression-free survival (PFS), PFS2 and overall survival (OS) in the ITT population.

III. To evaluate PFS, PFS2, and OS in the as-treated population. IV. To evaluate toxicity, including rates of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and other secondary malignancies, in the safety population.

EXPLORATORY OBJECTIVE:

I. To evaluate the moderating effect of physician-choice bevacizumab (as stratified) on randomized treatment effect estimates.

TRANSLATIONAL OBJECTIVES:

I. To assess BRCA reversion mutations in circulating tumor deoxyribonucleic acid (ctDNA) as a predictor of poor response in the BRCA mutated (BRCAm) population.

II. To correlate a combined assay assessing quantitative BRCA1 and RAD51C promoter methylation and pathogenic variants in core homologous recombination repair (HRR) genes with clinical homologous recombination deficiency (HRD) testing and outcomes in the BRCA wildtype (BRCAwt) population.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (REFERENCE): Patients receive olaparib orally (PO) twice daily (BID) on days 1-21 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and computed tomography (CT) and/or magnetic resonance imaging (MRI) throughout the study.

ARM II (EXPERIMENTAL): Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.

03

Conditions studied

  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor
  • FIGO Stage III Ovarian Cancer 2014
  • FIGO Stage IV Ovarian Cancer 2014
  • Ovarian Carcinoma
  • Ovarian Carcinosarcoma
  • Ovarian High Grade Endometrioid Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Primary Peritoneal Carcinosarcoma
  • Primary Peritoneal Endometrioid Adenocarcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma

Browse trials for

04

In context

Ovarian Neoplasms Reclassified

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

This study's planned enrollment of 880 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

NRG Oncology is the lead sponsor of 72 studies on the registry; 24 are open to participants now.

Compared within Ovarian Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with newly diagnosed, confirmed, Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer of the following types:

    • High grade serous
    • High grade endometrioid (excluding tumors that are known mismatch repair deficient/microsatellite instability high (MMR-D/MSI-H) or POLE ultramutated)
    • Carcinosarcoma (excluding tumors that are known mismatch repair deficient/microsatellite instability high (MMR-D/MSI-H) or POLE ultramutated), and/or
    • Other epithelial ovarian cancer with BRCA1/2 deleterious alteration (germline or somatic), (excluding tumors that are known mismatch repair deficient/microsatellite instability high (MMR-D/MSI-H) or POLE ultramutated)
    • Submission of pathology report is required
    • Ovarian cancer = ovarian, fallopian, or primary peritoneal cancer
  • Patients must have:

    • Documented variant (tumor or germline) in BRCA1 or BRCA2 that is predicted to be pathogenic or suspected pathogenic (deleterious alteration)

      • Submission of testing report is required. OR
    • BRCA 1/2 wildtype AND known HRD deficient tumor determined by any commercial or academic, Clinical Laboratory Improvement Act (CLIA)-certified laboratory (e.g., Myriad MyChoice©)

      • Submission of testing report is required
  • Patient must have undergone cytoreductive surgery (primary or interval)
  • Patients must have completed platinum-based therapy prior to registration:

    • Platinum based chemotherapy course must have consisted of a minimum of 4 treatment cycles and a maximum of 9, although it is strongly recommended that patients receive at least 6 cycles unless medically

      • For those receiving less than 6 cycles of platinum-based therapy, the reason for this must be documented and could include hematologic toxicity or non-hematologic toxicities directly related to therapy
    • Intravenous, intraperitoneal, or platinum-based chemotherapy is allowed; for weekly therapy, three weeks are considered one cycle
    • Patients must not have received an agent during their first line course of chemotherapy
  • Patients must have, in the opinion of the investigator, no clinical evidence of disease progression following completion of this chemotherapy course (partial or complete response to platinum-based chemotherapy)
  • Patients with treated are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression and patients are neurologically stable off therapy
  • Patients must be randomized at least 3 weeks and no more than 12 weeks after their last dose of chemotherapy (last dose is the day of the last infusion of platinum agent)
  • No previous treatment with a PARP inhibitor, including olaparib, niraparib, and rucaparib
  • Age ≥ 18
  • (ECOG) performance status of ≤ 2
  • Not pregnant and not nursing
  • (ANC) ≥ 1,500 cells/mm\^3
  • ≥ 100,000 cells/mm\^3
  • ≥ 9 g/dl
  • (CrCL) of > 30 mL/min by the Cockcroft-Gault formula
  • Total ≤ 1.5 x institutional (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
  • (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • No active infection requiring parental antibiotic(s)
  • No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube
  • No current inability to swallow orally administered medication
  • No history of myelodysplastic syndrome and/or acute myeloid leukemia
  • No history of bone marrow transplant
  • No concomitant use of strong or moderate inducers
  • No known to olaparib or any of the of the product
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
880 participants (estimated)

Study arms

  • Active comparator
    Arm I (olaparib, bevacizumab)

    Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.

    Biological: Bevacizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Olaparib

  • Experimental
    Arm II (olaparib, bevacizumab)

    Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.

    Biological: Bevacizumab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Olaparib

Interventions

  • BiologicalBevacizumab

    Given IV

    Also known as: ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avegra, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-aveg, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-byva, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-nwgd, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, Byvasda, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, IBI 305, IBI-305, IBI305, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Jobevne, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given PO

    Also known as: AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281

07

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) at least 360 days after randomization (PFS360)

    PFS will be tested using a one-sided, alpha = 0.05 level logrank test. Treatment hazard ratios and their 90% confidence intervals will be estimated using a Cox proportional hazards model specified with a main effect for the randomized treatment assignment and stratified using the stratification factors applied at randomization.

    Time frame: From completing 360 days of maintenance therapy to disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) or death, whichever occurs first, assessed up to 5 years

Secondary outcomes

  1. Overall survival (OS) 360

    This endpoint will be supported by the modified intent to treat (ITT) population, which excludes progressions, deaths or withdrawals within 359 days of randomization. Will be summarized using treatment hazard ratio estimates (90% confidence intervals). These estimates will be obtained from outcome-specific Cox-regression models specified with main effects for the randomized treatment and stratified by the factors included in the randomization. OS distributions will be summarized using methods developed by Kaplan-Meier.

    Time frame: From 360 days after randomization to death from any cause, assessed up to 5 years

  2. PFS

    Will be analyzed in the ITT population and serve as a sensitivity analysis for the primary endpoint. Will be summarized using treatment hazard ratio estimates (90% confidence intervals). These estimates will be obtained from outcome-specific Cox-regression models specified with main effects for the randomized treatment and stratified by the factors included in the randomization. PFS distributions will be summarized using methods developed by Kaplan-Meier.

    Time frame: From randomization to progression or death, whichever occurs first, or date of the last computed tomography scan if neither progression nor death has occurred, assessed up to 5 years

  3. PFS2

    PFS2 may be identified by objective radiological progression using Response Evaluation Criteria in Solid Tumors version (v)1.1., symptomatic deterioration or death. PFS2 will be summarized using treatment hazard ratio estimates (90% confidence intervals). These estimates will be obtained from outcome-specific Cox-regression models specified with main effects for the randomized treatment and stratified by the factors included in the randomization. PFS2 distributions will be summarized using methods developed by Kaplan-Meier.

    Time frame: From randomization to objective tumor progression on next-line treatment or death, assessed up to 5 years

  4. OS

    OS will be summarized using treatment hazard ratio estimates (90% confidence intervals). These estimates will be obtained from outcome-specific Cox-regression models specified with main effects for the randomized treatment and stratified by the factors included in the randomization. OS distributions will be summarized using methods developed by Kaplan-Meier.

    Time frame: From randomization to death, assessed up to 5 years

  5. Incidence of adverse events (AEs)

    Safety and tolerability will be graded using Common Terminology Criteria for Adverse Events v 5.0. AEs will be summarized by system organ class and preferred term according to the maximum grade observed for each patient.

    Time frame: Up to 30 days after last dose of study treatment

Other outcomes

  1. Effect of bevacizumab on PFS

    The estimates will be obtained from outcome-specific Cox regression models specified with main effects for the assigned treatment arm, physician-choice bevacizumab and the interaction term. The overall effect of bevacizumab will be described by the score test p value for the interaction term. Descriptively, the bevacizumab effect will be summarized using the randomized treatment hazard ratio estimates (95% confidence intervals) within the bevacizumab and no-bevacizumab subgroups (as stratified). PFS outcome distributions will further be described using methods developed by Kaplan-Meier.

    Time frame: Up to 5 years

  2. Effect of bevacizumab on OS

    The estimates will be obtained from outcome-specific Cox regression models specified with main effects for the assigned treatment arm, physician-choice bevacizumab and the interaction term. The overall effect of bevacizumab will be described by the score test p value for the interaction term. Descriptively, the bevacizumab effect will be summarized using the randomized treatment hazard ratio estimates (95% confidence intervals) within the bevacizumab and no-bevacizumab subgroups (as stratified). OS outcome distributions will further be described using methods developed by Kaplan-Meier.

    Time frame: Up to 5 years

  3. Effect of bevacizumab on PFS2

    The estimates will be obtained from outcome-specific Cox regression models specified with main effects for the assigned treatment arm, physician-choice bevacizumab and the interaction term. The overall effect of bevacizumab will be described by the score test p value for the interaction term. Descriptively, the bevacizumab effect will be summarized using the randomized treatment hazard ratio estimates (95% confidence intervals) within the bevacizumab and no-bevacizumab subgroups (as stratified). PFS2 outcome distributions will further be described using methods developed by Kaplan-Meier.

    Time frame: Up to 5 years

08

Study locations

682 of 709 sites recruiting

Showing the first 100 of 709 sites across 3 countries. Choose a country and city above to see the rest.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2034, 117 months after the start.

Of 52 non-industry phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 117 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Mar 12, 2025
Primary completionEst.
Dec 31, 2034
CompletionEst.
Dec 31, 2034
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 1 site removed. 13 sites changed recruiting status (6 now suspended, 4 now recruiting, …)
Show 13 sites
  • UCHealth University of Colorado Hospital · Aurora, United StatesRecruiting→Active, not recruiting
  • UCHealth - Cherry Creek · Denver, United StatesRecruiting→Active, not recruiting
  • UCHealth Highlands Ranch Hospital · Highlands Ranch, United StatesRecruiting→Active, not recruiting
  • Rush-Copley Medical Center · Aurora, United StatesRecruiting→Suspended
  • Rush-Copley Healthcare Center · Yorkville, United StatesRecruiting→Suspended
  • Memorial Hospital of South Bend · South Bend, United StatesRecruiting→Suspended
  • Walter Reed National Military Medical Center · Bethesda, United StatesSuspended→Recruiting
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesSuspended→Recruiting
  • Trinity Health Muskegon Hospital · Muskegon, United StatesSuspended→Recruiting
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
  • Summit Medical Group · Berkeley Heights, United StatesRecruiting→Suspended
  • Summit Health - Florham Park Campus · Florham Park, United StatesRecruiting→Suspended
  • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
Show 15 added (15 United States)
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United States
  • Sutter Health at SMSHCC · Oakland, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United States
  • Dominican Santa Cruz Hospital · Santa Cruz, United States
  • Stockton Hematology Oncology Medical Group · Stockton, United States
  • Orlando Health Cancer Institute - Doctor Phillips · Orlando, United States
  • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
  • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
  • HealthPartners Cancer Care - Park Nicollet Maple Grove · Maple Grove, United States
  • Fairview Cancer Center - Woodbury · Woodbury, United States
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center · Rio Rancho, United States
  • Albany Medical Center · Albany, United States
  • Smilow Cancer Hospital Care Center - Westerly · Westerly, United States
  • Providence Swedish Cancer Institute · Everett, United States
  • PeaceHealth Southwest Medical Center · Vancouver, United States
Show 1 removed
  • Newland Medical Associates-Pontiac · Pontiac, United States
Nov 9, 2026
Site contacts
Changed at 60 sites. See the sites
Show 60 sites
  • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
  • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
  • Stanford Cancer Center Emeryville · Emeryville, United StatesContact c•••@stanford.edu→c•••@stanford.edu
  • Mercy Cancer Center · Merced, United StatesContact person changed (no phone or email listed)
  • Stanford Cancer Institute Palo Alto · Palo Alto, United StatesContact c•••@stanford.edu→c•••@stanford.edu
  • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
  • Stanford Cancer Center South Bay · San Jose, United StatesContact c•••@stanford.edu→c•••@stanford.edu
  • Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo, United StatesContact person changed (no phone or email listed)
  • Mission Hope Medical Oncology - Santa Maria · Santa Maria, United StatesContact person changed (no phone or email listed)
  • Saint Joseph's Medical Center · Stockton, United StatesContact person changed (no phone or email listed)
  • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
  • UCHealth University of Colorado Hospital · Aurora, United StatesContact removed •••0650Contact removed (no phone or email listed)
  • Penrose-Saint Francis Healthcare · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • Rocky Mountain Cancer Centers-Penrose · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • Saint Francis Cancer Center · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • UCHealth - Cherry Creek · Denver, United StatesContact removed R•••@nrgoncology.org · •••5294Contact removed (no phone or email listed)
  • CommonSpirit Cancer Center Mercy · Durango, United StatesContact person changed (no phone or email listed)
  • Mercy Medical Center · Durango, United StatesContact person changed (no phone or email listed)
  • UCHealth Highlands Ranch Hospital · Highlands Ranch, United StatesContact removed •••0650Contact removed (no phone or email listed)
  • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United StatesContact person changed (no phone or email listed)
  • Longmont United Hospital · Longmont, United StatesContact person changed (no phone or email listed)
  • Saint Mary Corwin Medical Center · Pueblo, United StatesContact person changed (no phone or email listed)
  • Saint Anthony North Hospital · Westminster, United StatesContact person changed (no phone or email listed)
  • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
  • Rush-Copley Healthcare Center · Yorkville, United StatesContact removed C•••@rushcopley.com · •••6212Contact removed (no phone or email listed)
  • Memorial Hospital of South Bend · South Bend, United StatesContact removed •••7370Contact removed (no phone or email listed)
  • …and 30 more sites
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    15 sites added, 1 site removed. 13 sites changed recruiting status (6 now suspended, 4 now recruiting, …)
    Show 13 sites
    • UCHealth University of Colorado Hospital · Aurora, United StatesRecruiting→Active, not recruiting
    • UCHealth - Cherry Creek · Denver, United StatesRecruiting→Active, not recruiting
    • UCHealth Highlands Ranch Hospital · Highlands Ranch, United StatesRecruiting→Active, not recruiting
    • Rush-Copley Medical Center · Aurora, United StatesRecruiting→Suspended
    • Rush-Copley Healthcare Center · Yorkville, United StatesRecruiting→Suspended
    • Memorial Hospital of South Bend · South Bend, United StatesRecruiting→Suspended
    • Walter Reed National Military Medical Center · Bethesda, United StatesSuspended→Recruiting
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesSuspended→Recruiting
    • Trinity Health Muskegon Hospital · Muskegon, United StatesSuspended→Recruiting
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
    • Summit Medical Group · Berkeley Heights, United StatesRecruiting→Suspended
    • Summit Health - Florham Park Campus · Florham Park, United StatesRecruiting→Suspended
    • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
    Show 15 added (15 United States)
    • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United States
    • Sutter Health at SMSHCC · Oakland, United States
    • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United States
    • Dominican Santa Cruz Hospital · Santa Cruz, United States
    • Stockton Hematology Oncology Medical Group · Stockton, United States
    • Orlando Health Cancer Institute - Doctor Phillips · Orlando, United States
    • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
    • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
    • HealthPartners Cancer Care - Park Nicollet Maple Grove · Maple Grove, United States
    • Fairview Cancer Center - Woodbury · Woodbury, United States
    • Presbyterian Rust Medical Center/Jorgensen Cancer Center · Rio Rancho, United States
    • Albany Medical Center · Albany, United States
    • Smilow Cancer Hospital Care Center - Westerly · Westerly, United States
    • Providence Swedish Cancer Institute · Everett, United States
    • PeaceHealth Southwest Medical Center · Vancouver, United States
    Show 1 removed
    • Newland Medical Associates-Pontiac · Pontiac, United States
    Site contacts Changed at 60 sites. See the sites
    Show 60 sites
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • Stanford Cancer Center Emeryville · Emeryville, United StatesContact c•••@stanford.edu→c•••@stanford.edu
    • Mercy Cancer Center · Merced, United StatesContact person changed (no phone or email listed)
    • Stanford Cancer Institute Palo Alto · Palo Alto, United StatesContact c•••@stanford.edu→c•••@stanford.edu
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
    • Stanford Cancer Center South Bay · San Jose, United StatesContact c•••@stanford.edu→c•••@stanford.edu
    • Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Santa Maria · Santa Maria, United StatesContact person changed (no phone or email listed)
    • Saint Joseph's Medical Center · Stockton, United StatesContact person changed (no phone or email listed)
    • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
    • UCHealth University of Colorado Hospital · Aurora, United StatesContact removed •••0650Contact removed (no phone or email listed)
    • Penrose-Saint Francis Healthcare · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • Rocky Mountain Cancer Centers-Penrose · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • Saint Francis Cancer Center · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • UCHealth - Cherry Creek · Denver, United StatesContact removed R•••@nrgoncology.org · •••5294Contact removed (no phone or email listed)
    • CommonSpirit Cancer Center Mercy · Durango, United StatesContact person changed (no phone or email listed)
    • Mercy Medical Center · Durango, United StatesContact person changed (no phone or email listed)
    • UCHealth Highlands Ranch Hospital · Highlands Ranch, United StatesContact removed •••0650Contact removed (no phone or email listed)
    • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United StatesContact person changed (no phone or email listed)
    • Longmont United Hospital · Longmont, United StatesContact person changed (no phone or email listed)
    • Saint Mary Corwin Medical Center · Pueblo, United StatesContact person changed (no phone or email listed)
    • Saint Anthony North Hospital · Westminster, United StatesContact person changed (no phone or email listed)
    • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
    • Rush-Copley Healthcare Center · Yorkville, United StatesContact removed C•••@rushcopley.com · •••6212Contact removed (no phone or email listed)
    • Memorial Hospital of South Bend · South Bend, United StatesContact removed •••7370Contact removed (no phone or email listed)
    • …and 30 more sites
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06580314
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Mar 12, 2025
Primary completion
Dec 31, 2034 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Nov 9, 2026

Study contacts

Ying Liu
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Olaparib

Start the discussion